Anti-Müllerian Hormone as a Sensitive Marker of Ovarian Function in Young Cancer Survivors

Table 2

Serum levels of FSH, LH, E2, and AMH in female cancer survivors according to risk groups and comparison to control group.

Study group	𝑛	Hormones	𝑋	𝑀	SD	𝑃
Whole group	83	FSH (mIU/mL)	12.24	7.01	19.41	0.001
HR	38		18.11	7.64	28.71	0.005
MR	12		7.43	7.16	2.77	0.964
LR	33		8.95	6.44	9.63	0.679
Control	34		5.36	5.15	1.89
Whole group	83	LH (mIU/mL)	7.73	4.49	11.32	0.449
HR	38		10.23	4.10	17.01	0.106
MR	12		5.34	4.42	4.33	1
LR	33		6.44	4.77	5.15	0.924
Control	34		5.52	4.68	4.1
Whole group	83	E2 (pg/mL)	45.42	32.5	54.72	0.057
HR	38		52.21	33.29	69.20	1
MR	12		51.39	17.60	75.46	0.999
LR	33		38.38	33.20	28.99	0.491
Control	34		53.32	47.39	41.14
Whole group	83	AMH (pmol/L)	16.7	11.58	14.13	0.001
HR	38		14.14	9.89	13.26	0.001
MR	12		14.82	8.54	16.19	0.019
LR	33		19.44	19.00	13.96	0.053
Control	34		27.03	25.26	12.31

HR: high risk, MR: medium risk, LR: low risk, FSH: follicle-stimulating hormone, LH: luteinizing hormone, E2: estradiol, AMH: anti-Müllerian hormone, 𝑋: average value, and 𝑀: median.